Actinium Pharmaceuticals (NYSE:ATNM) Announces Earnings Results

Actinium Pharmaceuticals (NYSE:ATNM) released its quarterly earnings results on Monday. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02, Yahoo Finance reports.

Actinium Pharmaceuticals Stock Performance

Shares of NYSE:ATNM opened at $2.79 on Wednesday. Actinium Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $10.24. The firm has a market cap of $83.09 million, a PE ratio of -1.63 and a beta of 0.20.

Analyst Ratings Changes

A number of research analysts have commented on the company. Maxim Group lowered their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday. HC Wainwright decreased their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday. StockNews.com lowered Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. Finally, Stephens began coverage on Actinium Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.77.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.